Detection of HIV-1-associated neurocognitive disorders

US10161925B2 · kind B2 · utility

Assignees

• Temple University-Of The Commonwealth System of Higher Education · US
• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• Salim Merali · Queens, US
• Carlos A. Barrerro · Philadelphia, US
• Kamel Khalili · Yeadon, US
• Jay Rappaport · Somers Point, US
• Norman Haughey · Baltimore, US
• Ned Sacktor · Baltimore, US

Key dates

• Filing date: Mar 24, 2015
• Grant date: Dec 25, 2018
• Expiry date: Jun 9, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/56
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Provided is a method of detecting mild neurocognitive disturbance (MNCD) or HIV associated dementia (HAD) in a patient comprising detecting the level of acetyl spermine and/or acetyl spermidine from a cerebrospinal fluid test sample of the patient; and comparing the level of acetyl spermine and/or acetyl spermidine in the test sample to the level of the acetyl spermine and/or acetyl spermidine in a cerebrospinal fluid control sample or to a control value for lack of neurocognitive impairment, MNCD or HAD; wherein an elevated level of acetyl spermine and/or acetyl spermidine in the test sample as compared to the level in the control sample or a control value for lack of neurocognitive impairment, or a level of acetyl spermine and/or acetyl spermidine that is similar to that of a control value for MNCD or HAD, indicates that the patient suffers from MNCD or HAD. Also provided are methods for measuring the progression of an HIV-1-associated neurocognitive disorder, as well as methods for staging such a disorder.